Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiangju Rupining Capsule for Mammary Gland Hyperplasia (Qi Stagnation and Blood Stasis) Phase II Trial
CTR20182526Phase 2Active
- Sponsor
- Wuhan Pharmaceutical Valley Technology Development
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xiangju rupining in breast hyperplasia, sponsored by Wuhan Pharmaceutical Valley Technology Development. Started Jan 2019; status: active.
02
Drugs
xiangju rupining
03
Conditions
breast hyperplasia
Beyond the preview
Go deeper on CTR20182526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182526.